Home › Compare › BMNDF vs EQR

BMNDF vs EQR: Dividend Comparison 2026

BMNDF yields 18181.82% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BMNDF wins by $658834.81M in total portfolio value
10 years
BMNDF
BMNDF
● Live price
18181.82%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$658834.86M
Annual income
$54,543,841,013.90
Full BMNDF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — BMNDF vs EQR

📍 BMNDF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMNDFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMNDF + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BMNDF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMNDF
Annual income on $10K today (after 15% tax)
$1,545,454.55/yr
After 10yr DRIP, annual income (after tax)
$46,362,264,861.82/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, BMNDF beats the other by $46,362,260,207.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMNDF + EQR for your $10,000?

BMNDF: 50%EQR: 50%
100% EQR50/50100% BMNDF
Portfolio after 10yr
$329417.45M
Annual income
$27,271,923,244.75/yr
Blended yield
8.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

BMNDF
No analyst data
Altman Z
-414.3
Piotroski
1/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMNDF buys
0
EQR buys
0
No recent congressional trades found for BMNDF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMNDFEQR
Forward yield18181.82% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%15.8% ✓
Portfolio after 10y$658834.86M ✓$47.8K
Annual income after 10y$54,543,841,013.90 ✓$5,475.61
Total dividends collected$553757.55M ✓$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: BMNDF vs EQR ($10,000, DRIP)

YearBMNDF PortfolioBMNDF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$919,791$909,090.91$11,380$679.82+$908.4K → BMNDF
2$40,057,707$39,073,530.55$13,014$837.25+$40.04M → BMNDF
3$838,042,485$795,180,738.70$14,961$1,036.20+$838.03M → BMNDF
4$8,670,481,609$7,773,776,150.53$17,297$1,289.22+$8670.46M → BMNDF
5$46,860,761,379$37,583,346,056.88$20,121$1,613.15+$46860.74M → BMNDF
6$145,058,842,015$94,917,827,338.98$23,561$2,030.84+$145058.82M → BMNDF
7$292,512,437,337$137,299,476,380.97$27,783$2,573.54+$292512.41M → BMNDF
8$442,364,760,258$129,376,452,307.77$33,013$3,284.39+$442364.73M → BMNDF
9$564,757,963,223$91,427,669,747.44$39,547$4,223.51+$564757.92M → BMNDF
10$658,834,861,663$54,543,841,013.90$47,791$5,475.61+$658834.81M → BMNDF

BMNDF vs EQR: Complete Analysis 2026

BMNDF — Stock

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's-type cognitive impairment. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammation, and BMND07 for treating major depressive disorder. The company is headquartered in Canelones, Uruguay.

Full BMNDF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this BMNDF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMNDF vs SCHDBMNDF vs JEPIBMNDF vs OBMNDF vs KOBMNDF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.